Ocular Therapeutix Inc (NAS:OCUL)
$ 5.8 -0.2 (-3.33%) Market Cap: 898.36 Mil Enterprise Value: 520.85 Mil PE Ratio: 0 PB Ratio: 2.20 GF Score: 79/100

Ocular Therapeutix Inc Corporate Call Transcript

Sep 27, 2022 / 12:00PM GMT
Release Date Price: $4.31 (-18.37%)
Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Ocular Therapeutics conference call announcing interim results for its U.S.-based Phase I clinical trial of OTX-TKI for the treatment of wet AMD. (Operator Instructions) It is now my pleasure to turn the call over to Donald Notman, Chief Financial Officer of Ocular Therapeutics. Please go ahead, sir.

Donald Notman
Ocular Therapeutix, Inc. - CFO

Thank you, Shannon. Good morning, everyone, and thank you for joining us on our conference call to discuss interim results from our U.S.-based Phase I clinical trial of OTX-TKI for the treatment of wet AMD. The press release can be accessed on the Investors portion of our website at investors.ocutx.com.

Leading the call today will be Antony Mattessich, our President and Chief Executive Officer, who will also be joined by Dr. Rabia Gurses Ozden, our Chief Medical Officer; and Dr. Peter Kaiser, our Chief Medical Adviser, Retina. Following our prepared remarks, we will open the line for your questions.

As a reminder, on today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot